Investment Rating - The report maintains a "Recommended" rating for the agricultural, forestry, animal husbandry, and fishery industry [1] Core Views - The report highlights that the de-stocking of live pigs may accelerate, with a focus on the value reassessment opportunities in the pig sector due to ongoing regulatory measures [3][4] - The poultry sector is expected to see improvements in its fundamentals, while the animal health sector is poised for performance recovery and advancements in African swine fever vaccine clinical trials [5][6] - The pet economy is thriving, with strong growth in domestic brands, indicating a rapid development phase for the pet industry [9][10] Summary by Sections 1. Swine - The swine industry is undergoing deepening regulatory measures aimed at controlling prices through capacity reduction. Short-term pressures on pig prices are anticipated due to increased market supply and inventory adjustments. The expectation is for a gradual policy approach rather than aggressive interventions [3][4][15] - Key companies recommended include Muyuan Foods and Wens Foodstuffs, with additional attention on Dekang Agriculture, Shennong Group, and Juxing Agriculture [3][16] 2. Poultry - The poultry sector shows signs of fundamental improvement, with data indicating a rise in the number of breeding stock and a shift towards self-breeding [4][25] - Recommendations include Shennong Development and Lihua Stockbreeding, as the industry navigates through low price periods [4][25] 3. Animal Health - The animal health sector has seen revenue and profit growth among listed companies, with notable performances from Reap Bio and Keqian Bio. The clinical trials for African swine fever vaccines are progressing, which may enhance market prospects [5][32] - Recommended companies include Keqian Bio, Reap Bio, and attention on Huazhong Bio and other related firms [5][32] 4. Planting - Grain prices are on the rise, with significant increases in corn and soybean meal prices noted. The commercialization of genetically modified seeds is progressing, benefiting companies with early investments in research and development [7][37] - Companies to watch include Suqian Agricultural Development, Longping High-Tech, and Denghai Seeds [7][42] 5. Feed - The feed industry is experiencing price fluctuations, with a noted increase in production volume. The concentration of the industry is expected to continue rising [8][43] - Recommended companies include Haida Group and Hefa Shares [8][45] 6. Pets - The pet market is projected to reach a scale of 300.2 billion yuan in 2024, with significant growth in both dog and cat segments. The report emphasizes the rapid development of domestic brands in this sector [9][54] - Recommended companies in the pet food sector include Guibao Pet, Zhongchong Shares, and Petty Shares, with a focus on the medical segment as well [9][55]

Core Insights - The report maintains a positive outlook on the agricultural sector, particularly in pig farming, despite ongoing supply pressures and potential acceleration in capacity reduction [1][5][6]. Group 1: Pig Farming - Supply pressures continue to be significant, with a reported decrease in the number of breeding sows by 0.77% month-on-month in October [5][17]. - The average price of market pigs has declined to 12.16 CNY/kg as of November 6, reflecting a week-on-week decrease of 0.49% [5][26]. - The profitability of pig farming remains negative, with losses reported at -89.21 CNY per head for self-bred pigs and -175.54 CNY per head for purchased piglets as of November 7 [5][37]. Group 2: Poultry Farming - The average price of white feather broilers remained stable at 7.09 CNY/kg as of November 7, with a reported loss of -1.25 CNY per bird [5][38]. - The number of breeding chickens has increased significantly, with a 143.18% month-on-month rise in the number of grandparent stock updated in October [5][38]. Group 3: Animal Health - The demand for animal health products is expected to rebound, driven by a recovery in breeding cycles and an increase in inventory levels [5][47]. - The report highlights the ongoing development of vaccines, including progress in African swine fever vaccine trials, which may enhance the sector's growth potential [5][47]. Group 4: Seed Industry - The average prices for wheat, soybean meal, and corn have shown slight declines, with wheat at 2487 CNY/ton, soybean meal at 3098 CNY/ton, and corn at 2239 CNY/ton as of November 7 [5][51]. - The report emphasizes the importance of food security and the promotion of biotechnology in the seed industry [5][51]. Group 5: Pet Industry - Pet food exports amounted to 823 million CNY in September, reflecting a year-on-year decrease of 6.8%, while domestic sales continue to grow, with a 3% increase across major e-commerce platforms [5][56][59]. - The report suggests that companies with a lower proportion of export business may be less affected by tariff disruptions, while those focusing on domestic growth are likely to enhance their market share [5][56][59].

Investment Rating - Industry Rating: Outperform the market (maintained rating) [9] Core Views - The swine sector continues to experience losses, with an increasing number of culled sows, indicating a need to focus on the expected recovery in this sector [2][13] - The dairy and beef sectors are undergoing significant capacity reduction, with a potential turning point for milk prices anticipated [3][15] - The pet sector is witnessing a trend towards premiumization and the rise of domestic brands, reshaping the competitive landscape [4][16] - The poultry sector is facing challenges with breeding stock shortages and improving consumer demand for yellow chickens [5][18] - The seed industry is poised for a turnaround, with an emphasis on biotechnology and the commercialization of genetically modified crops [7][23] - The feed sector shows signs of recovery, with leading companies like Haida Group achieving revenue and profit growth [24][26] Summary by Sections Swine Sector - The industry continues to face losses, with the average price of live pigs at 12.02 CNY/kg, down 4.07% from the previous week [13] - The average market value per head for leading companies is at historical low levels, with Muyuan at 3000-3500 CNY/head and Wens at 2000-3000 CNY/head [14] - Recommended stocks include leading breeders like Muyuan and Wens, with additional focus on flexible stocks such as Shennong Group and Dekang Agriculture [14] Beef Sector - The price of beef cattle is showing signs of stabilization, with the average price for fattened bulls at 25.62 CNY/kg [15] - The dairy cow population has decreased by 8%, indicating a significant capacity reduction [15] - Companies with mother cow resources or those adopting a "milk-meat linkage" model are expected to have stronger profitability [15] Pet Sector - The Double Eleven shopping festival highlighted the resilience and structural upgrades in the pet food market, with domestic brands gaining market share [4][16] - Key recommendations include pet food brands like Guibao Pet and Zhongchong Co., with a focus on companies with technological advantages and comprehensive product lines [17] Poultry Sector - The white chicken sector is under pressure due to breeding stock shortages, with a focus on the impact of avian influenza on imports [18][19] - Yellow chicken prices are expected to improve due to supply constraints and increasing consumer demand [20] - Recommended stocks include leading companies like Shennong Development and Yisheng Biological [19] Seed Sector - The seed industry is expected to benefit from increased focus on food security and the commercialization of genetically modified crops [7][23] - Key recommendations include leading seed companies like Longping High-Tech and Dabeinong [23] Feed Sector - Haida Group is highlighted as a key player in the feed sector, with significant market share growth and revenue increases [24][26] - The overall feed market is expected to recover as smaller companies exit the market, leading to improved conditions for remaining players [24]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative return of over 20% within the next six months [7][18]. Core Insights - The company achieved a revenue of 738 million yuan in the first three quarters of 2025, representing an 11% year-on-year increase, and a net profit attributable to shareholders of 338 million yuan, up 30% year-on-year [1]. - The core products have established a solid foundation for profitability, with a 24% year-on-year increase in vaccine issuance volume, outperforming the industry average of 17% [2]. - The company has a strong R&D capability, with R&D expenses accounting for 9.74% of total revenue in Q3 2025, leading to the successful launch of multiple new products, including a dual vaccine for swine fever and pseudorabies [3]. - Despite challenges in the industry, including price wars due to homogenization, the report suggests that the market is nearing a recovery phase as some companies exit the market [4]. Financial Performance Summary - For Q3 2025, the company reported a revenue of 251 million yuan, a 5% decrease year-on-year but a 4% increase quarter-on-quarter [1]. - The gross margin and net margin for Q3 were 66.33% and 46.82%, respectively, with net margin improvement driven by non-recurring gains [2]. - The report forecasts revenues of 1.06 billion yuan, 1.29 billion yuan, and 1.5 billion yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 13%, 21%, and 17% [4][6].

Core Insights - The animal health sector experienced a slight increase of 0.55% on November 7, with *ST Lvkang leading the gains [1] - The Shanghai Composite Index closed at 3997.56, down 0.25%, while the Shenzhen Component Index closed at 13404.06, down 0.36% [1] Stock Performance - *ST Lvkang (002868) closed at 31.76, up 4.99% with a trading volume of 12,000 hands and a transaction value of 37.6483 million yuan [1] - Other notable stocks included: - Biological Shares (600201) at 10.52, up 1.64% with a trading volume of 234,300 hands [1] - Driving Force (920275) at 9.88, up 1.13% with a trading volume of 7,484 hands [1] - Zhongmu Shares (600195) at 7.75, up 0.65% with a trading volume of 77,200 hands [1] Capital Flow - The animal health sector saw a net outflow of 5.144 million yuan from institutional investors, while retail investors experienced a net outflow of 11.0652 million yuan [2] - Conversely, speculative funds recorded a net inflow of 16.2092 million yuan [2] Detailed Capital Flow Analysis - Major stocks and their capital flow included: - Biological Shares (600201) with a net inflow of 20.3753 million yuan from institutional investors [3] - *ST Lvkang (002868) had a net inflow of 2.9042 million yuan from institutional investors [3] - Huisheng Biological (300871) faced a significant net outflow of 18.6925 million yuan from institutional investors [3]

Core Insights - The animal health sector experienced a slight increase of 0.36% on November 6, with *ST Lvkang leading the gains [1] - The Shanghai Composite Index closed at 4007.76, up 0.97%, while the Shenzhen Component Index closed at 13452.42, up 1.73% [1] Stock Performance - *ST Lvkang (002868) closed at 30.25, with a rise of 5.00% and a trading volume of 32,200 hands, amounting to a transaction value of 96.94 million yuan [1] - Other notable stocks include: - KQ Bio (688526) at 16.07, up 0.69% [1] - Biological Shares (600201) at 10.35, up 0.68% with a transaction value of 153 million yuan [1] - Ruipu Biological (300119) at 20.46, up 0.20% [1] - Pulaike (603566) at 14.09, up 0.14% [1] Capital Flow - The animal health sector saw a net outflow of 17.47 million yuan from institutional investors, while retail investors contributed a net inflow of 8.89 million yuan [2] - The capital flow for individual stocks indicates: - *ST Lvkang had a net inflow of 7.56 million yuan from institutional investors [3] - KQ Bio experienced a net inflow of 4.84 million yuan [3] - Biological Shares had a net inflow of 2.64 million yuan [3]

Group 1 - The core viewpoint of the news is the initiation of large-scale clinical trials for gene-edited pig kidneys for human transplantation, marking a significant advancement in biotechnology and organ transplantation [1] - The first clinical trial was completed at NYU Langone Medical Center, approved by the FDA, aiming to evaluate the safety and efficacy of gene-edited pig kidneys for patients with end-stage kidney disease [1] - Global advancements in gene editing technology have been reported, including successful transplantation of gene-edited pig lungs in China and new treatment approaches for Down syndrome in Japan [1] Group 2 - Huazhong Securities highlights that breakthroughs in gene editing technology have significantly lowered the technical barriers for genetic modification, enabling large-scale industrial production of drugs [2] - In the A-share market, there are 22 listed companies with gene editing technology reserves, with mixed performance in stock prices; only 7 out of 22 companies saw gains on November 5 [4] - Among gene editing concept stocks, Shuanglu Pharmaceutical reported the highest net profit of 141 million yuan in the first three quarters, while Mengcao Ecological achieved a year-on-year profit increase of 48.73% [5][6] Group 3 - Eight gene editing concept stocks received attention from five or more institutions, with companies like Sturdy Medical and Huaxi Biological leading in institutional ratings [7] - Sturdy Medical announced a collaboration with Huazhong Agricultural University to establish a cotton research institute, focusing on gene editing and hybridization techniques for cotton seed improvement [7]

Group 1 - The core point of the news is the initiation of large-scale clinical trials for gene-edited pig kidneys for human transplantation, marking a significant breakthrough in gene editing technology [1] - The trials are approved by the FDA and aim to systematically evaluate the safety and efficacy of gene-edited pig kidneys for patients with end-stage kidney disease [1] - There have been multiple advancements in gene editing technology globally, including successful transplants of gene-edited organs and new treatment approaches for genetic disorders [1] Group 2 - Huazhong Securities notes that breakthroughs in gene editing technology have significantly lowered the technical barriers for genetic modification, enabling large-scale industrial production and reducing drug production costs [2] - A total of 22 listed companies in the A-share market have gene editing technology reserves, with several companies reporting profitability in their third-quarter results [3] - Notable companies include Shuanglu Pharmaceutical, which reported a net profit of 141 million yuan, and Mengcao Ecological, which saw a 48.73% year-on-year increase in net profit [3][4] Group 3 - Companies like Wanjian Medical are collaborating with research institutions to develop cotton varieties using gene editing technology, indicating the application of gene editing beyond human health [5] - The number of institutional ratings for gene editing concept stocks shows significant interest, with companies like Wanjian Medical and Huaxi Biological receiving the highest number of ratings [6]

Core Insights - The animal health sector experienced a decline of 0.35% on November 3, with Reap Bio leading the losses [1] - The Shanghai Composite Index closed at 3976.52, up 0.55%, while the Shenzhen Component Index closed at 13404.06, up 0.19% [1] Stock Performance Summary - Hai Li Biological (603718) closed at 7.02, up 2.03% with a trading volume of 101,600 shares and a turnover of 70.93 million yuan [1] - Shen Lian Biological (688098) closed at 11.36, up 1.43% with a trading volume of 133,100 shares and a turnover of 150 million yuan [1] - Yong Shun Biological (920729) closed at 10.09, up 1.00% with a trading volume of 23,800 shares and a turnover of 24.09 million yuan [1] - The worst performer was Reap Bio (300119), which closed at 21.01, down 2.51% with a trading volume of 103,300 shares and a turnover of 219 million yuan [2] Capital Flow Analysis - The animal health sector saw a net outflow of 35.26 million yuan from institutional investors, while retail investors had a net inflow of 26.79 million yuan [2] - The main capital inflow was observed in Shen Lian Biological, with a net inflow of 4.03 million yuan from institutional investors [3] - Conversely, Reap Bio experienced a net outflow of 1.29 million yuan from institutional investors [3]

证券代码：688526 证券简称：科前生物 公告编号：2025-055 武汉科前生物股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 11 月 18 日 （星期二） 11:00-12:00 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 11 月 11 日 （星期二） 至 11 月 17 日 （星 期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目 或通过公司邮箱 wuhankqbio@kqbio.com 进行提问。公司将在说明会 上对投资者普遍关注的问题进行回答。 本次业绩说明会以网络互动形式召开，公司将针对 2025 年第三 季度的经营成果及财务指标的具体情况与投资者进行互动交流和沟 通，在信息披露允许的范围内就投资者普遍关注的问题进行回答。 武汉科前生物股份有限公司（以下简称"公 ...